CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta for the treatments of primary biliary cholangitis (PBC). The company also develops MBX-2982, a G protein-coupled receptor 119 (GPR119) agonist, in subjects with type 1 diabetes. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Fremont, California. As of March 22, 2024, CymaBay Therapeutics, Inc. operates as a subsidiary of Gilead Sciences, Inc.
Research context
Cymabay Therapeu appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
5 years, 6 months ago
CymaBay Therapeutics, Inc is currently in a long term downtrend where the price is trading 24.6% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.0.
CymaBay Therapeutics, Inc's total revenue sank by nan% to $0 since the same quarter in the previous year.
Its net income has increased by 46.4% to $-16M since the same quarter in the previous year.
Finally, its free cash flow grew by 47.4% to $-15M since the same quarter in the previous year.
Based on the above factors, CymaBay Therapeutics, Inc gets an overall score of 3/5.